English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Emerging evidence confirms a central role of Akt in cancer. To evaluate the relative contribution of deregulated Akt and their clinicopathological significance in lung carcinomas, overexpression, activation of Akt and   AKT   gene increases were investigated. Immunohistochemical staining for 108 cases revealed overexpression of total Akt, Akt1, Akt2 and Akt3 in 61.1, 47.2, 40.7 and 23.1%, respectively, and phosphorylated Akt in 42.6% of cases. Expression of total Akt, Akt2 and Akt3 were frequently observed in small cell carcinoma, but phosphorylated Akt and Akt1 were more frequently observed in squamous cell carcinoma.  FISH  analysis to evaluate gene increases of   AKT 1‐3  revealed amplification of   AKT 1  in 4.2% and   AKT 1  increase by polysomy of chromosome 14 in 27.3% of cases. For   AKT 2,  amplification was observed in 3.2% and polysomy of chromosome 19 in 26.3% of cases.   AKT 3  increase was observed in 40.0% of cases only by polysomy of chromosome 1. Although “ FISH ‐positive”   AKT 1  and   AKT 2  gene increases (amplification/high‐level polysomy) were found exclusively in the cases overexpressing total Akt, Akt1 or Akt2, respectively,   AKT 3  increase was irrelevant of Akt3 expression. Statistically, expressions of Akt2, p‐Akt and cytoplasmic‐p‐Akt were correlated with lymph node metastasis ( P  = 0.0479,  P  = 0.0371 and  P  = 0.0310, respectively). Although   AKT 1  and   AKT 2  gene increase showed positive correlation with, or trend towards a positive correlation with tumor size ( P  = 0.0430,  P  = 0.0590, respectively),   AKT 3  did not. In conclusion, Akt isoforms are differentially involved in the pathological phenotype of lung carcinoma in a diverse manner. Because abnormality of Akt1/  AKT 1  and Akt2/  AKT 2  correlated with clinicopathological profiles, Akt1/2‐specific targeting may open a novel therapeutic window for the group showing Akt deregulation.

Diverse involvement of isoforms and gene aberrations of Akt in human lung carcinomas